Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 6Mouth Neoplasms 3Squamous Cell Carcinoma of Head and Neck 2Tongue Neoplasms 1Solid Tumor 1Skin Lesion 1Renal Colic 1Rectal Neoplasms 1Pregnancy, Ectopic 1Postoperative Complications 1Pneumonia 1Pleural Effusion 1Phlebitis 1Pancreatic Neoplasms 1Lymphoma, Primary Effusion 1Lymphoma, B-Cell 1Lymphoma, AIDS-Related 1Liver Neoplasms 1Kidney Neoplasms 1Gastrointestinal Neoplasms 1Cysts 1Cholecystitis 1Brain Neoplasms 1Arachnodactyly 1Abortion, Spontaneous 1

Interventions

varlilumab 1liposomal doxorubicin 1etoposide phosphate 1Vincristine 1Ultrasonography 1Rituximab 1Prednisone 1Nivolumab 1Lenalidomide 1Immunoglobulin G 1Etoposide 1Endoscopy 1Electrocardiography 1Echocardiography 1Doxorubicin 1Disulfides 1Cyclophosphamide 1Bronchoscopy 1Bone Marrow Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Primary Effusion × Ultrasonography × 1 year × Clear all
NCT02911142 2025-07-28

Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1/2 Active not recruiting
17 enrolled 21 charts
Lymphoid

Lymphoma, B-Cell, Lymphoma, AIDS-Related, Lymphoma, Primary Effusion

Data powered by HemOnc (CC BY 4.0) Colophon âš¡